<DOC>
	<DOCNO>NCT00863551</DOCNO>
	<brief_summary>This study evaluate penetration blood-brain-barrier trospium chloride plasma steady state ( Day 10 ) elderly subject overactive bladder symptom . Trospium level cerebrospinal fluid ( CSF ) peak trough plasma level measure . Baseline day 10 post-dose neurocognitive testing compare use reliable change index ass study subject show evidence clinically statistically significant change memory .</brief_summary>
	<brief_title>Sanctura Muscarinic Receptor Antagonist Resists Transport ( SMART ) Trial</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder , Overactive</mesh_term>
	<mesh_term>Trospium chloride</mesh_term>
	<criteria>Male female , 6575 year age without evidence memory impairment Subject overactive bladder symptom otherwise healthy Nonsmoker ( refrain tobacco usage , include smokeless tobacco , nicotine patch , etc. , 6 month prior screen visit ) Weight within normal range Ability follow study instruction likely complete require visit Residual urine within bladder great 4 ounce Moderate severe memory impairment Bleeding disorder Bloodthinning agent Concurrent overactive bladder medication Concurrent dementia drug : Aricept ( donepezil ) , Namenda ( memantine ) , Cognex ( tacrine ) , Exelon ( rivastigmine ) , Razadyne ( galantamine ) , galantamine similar drug dementia Chronic kidney failure Abdominal bypass surgery obesity</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>